BMO Capital initiated coverage of Protagonist Therapeutics (PTGX) with an Outperform rating and $62 price target The firm says Protagonist is leveraging its peptide technology platform to address hematology and immunology disorders. It expects the shares to continue to appreciate on clinical de-risking of its pipeline over the next 12 months with several catalysts for rusfertide and JNJ-2113. Protagonist can deliver oral options in mega-blockbuster categories currently dominated by injectables, contends BMO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities
- Protagonist Therapeutics price target raised to $67 from $51 at BTIG
- Protagonist Therapeutics selects PN-881 as development candidate
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Protagonist Therapeutics Reports Strong Financial Turnaround
Questions or Comments about the article? Write to editor@tipranks.com